Global design and technology services provider Tata Elxsi has partnered strategically with San Francisco-based software 3.0 AI platform KAVIA AI. The company claims that this is designed to manage millions of lines of code and intricate backend
Fujifilm India, the pioneer in healthcare technology, has introduced Endoveda, a smart endoscopy report management application, at the conference ENDOCON 2025 held in Jaipur.
In one of the most significant advancements in medtech, scientists have presented a smart capsule capable of monitoring and treating inflammation of the gut in real-time, which his manageable via smartphone app...
In a remarkable turn of events in the pharmaceutical trade globally, the API China 2025 has concluded its proceedings with a life-colored presence and thriving industry participation. The main event highlighted booming demand of active pharma...
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended donanemab for the treatment of early symptomatic Alzheimer's disease in adults with confirmed amyloid pathology who are heterozygotes
Apollo Hospitals and Siemens Healthineers have announced a strategic research alliance to foster innovation in liver disease diagnostics leveraging artificial intelligence (AI) and imaging, with a focus on developing AI-enabled clinical tools
In a major leap for India's biotech industry, accessible CAR-T therapy has not only reached patients sooner than expected but has also become commercially viable. ImmunoACT, the startup that created India's first indigenous CAR-T cell therapy...
As part of a trend that is causing concern in the industry regarding the quality of drugs and adherence to across-the-board manufacturing standards, major Indian drugmakers such as Sun Pharma, Lupin and Dr Reddy Laboratories have initiated volunt...
Patent specialists are sounding the alarm about the intellectual property terms in the recently finalized India-UK Trade Pact, which they claim will restrict India's ability to ensure affordable access to essential medicines...
Pfizer has entered a worldwide license deal, with the exception of China, with Chinese company 3SBio to obtain exclusive rights to develop, make, and sell 3SBio's investigational bispecific antibody, SSGJ-707.
, CDSCO.jpg)
